AQP4 and myeloid sarcoma: One recent study that combined GFAP and glutamine synthetase (GS) analyses found that markers of astrocytic damage were higher in patients with AQP4-IgG NMOSD when compared to MS, but also found some seronegative NMOSD patients with high levels of GFAP and GS (113).